Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study.

CONCLUSIONS: In patients with MEN 2 syndrome phaeochromocytomas are usually benign adrenal tumours with high risk of bilateral development. Taking to account the latter risk and non-specific clinical manifestation of the neoplasm it is mandatory to screen all RET proto-oncogene mutations carriers for phaeochromocytoma. (Endokrynol Pol 2016; 67 (1): 54-58). PMID: 26884116 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/26884116?dopt=Abstract

Source: Endokrynologia Polska - February 19, 2016 Category: Endocrinology Authors: Kotecka-Blicharz A, Hasse-Lazar K, Jurecka-Lubieniecka B, Oczko-Wojciechowska M, Pawlaczek A, Bugajska B, Ledwon A, Król A, Michalik B, Jarząb B Tags: Endokrynol Pol Source Type: research